Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
4(57.1%)
Phase 1
3(42.9%)
7Total
Early Phase 1(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06364852Phase 1Recruiting

An Evaluation of LY007 Cell Injection for r/r B-NHL

Role: collaborator

NCT06279611Phase 1Recruiting

An Evaluation of LY007 Cell Injection for r/r B-NHL

Role: lead

NCT04977193Early Phase 1Unknown

A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma

Role: lead

NCT04966143Early Phase 1Unknown

Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer

Role: lead

NCT04169932Early Phase 1Unknown

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

Role: lead

NCT04166838Early Phase 1Unknown

The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

Role: lead

NCT03207178Phase 1Unknown

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

Role: lead

All 7 trials loaded